Dr. Levine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
462 First Avenue
New York, NY 10016- Is this information wrong?
Summary
- Douglas A. Levine is a Gynecologic Oncologist and Translational Scientist, now serving as Senior Principal Scientist at Merck Research Labs. He previously was Director of the Gynecologic Oncology Division at the New York University Langone Medical Center in New York City. Prior to that he was an Attending Surgeon on the faculty at MSKCC for many years. He received his M.D. from Mount Sinai School of Medicine and completed his residency at Mount Sinai Medical Center and a fellowship at Memorial Sloan Kettering. In addition to his clinical practice, Dr. Levine served as Head of the Gynecology Research Laboratory at MSK and NYU, where he studied cancer prevention, precision medicine, and rare tumors with unmet needs. Dr. Levine has an outstanding level of expertise and leadership in ovarian and endometrial cancer research and a deep commitment to women’s health.
Education & Training
- Memorial Sloan Kettering Cancer CenterPost-Doctoral Fellowship, Molecular Genetics, 2002 - 2004
- Memorial Sloan Kettering Cancer CenterFellowship, Gynecologic Oncology, 1999 - 2002
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Obstetrics and Gynecology, 1995 - 1999
- Icahn School of Medicine at Mount SinaiClass of 1995
Certifications & Licensure
- NY State Medical License 1996 - 2025
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- 1 citationsThe role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.Amnon A Berger, Emily A Kawaler, Fanny Dao, Selim Misirlioglu, Ernesto Arostegui Fernandez, Narciso Olvera, Elke Van Oudenhove, Deborah DeLair, Douglas A Levine> ;Gynecologic Oncology. 2022 Nov 1
- 2 citationsMolecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.Elaine Stur, Emine Bayraktar, Graziela Zibetti Dal Molin, Sherry Y Wu, Lingegowda S Mangala, Hui Yao, Ying Wang, Prahlad T Ram, Sara Corvigno, Hu Chen, Han Liang, Shel...> ;Cancers. 2022 Aug 30
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.Eileen O Dareng, Jonathan P Tyrer, Daniel R Barnes, Michelle R Jones, Xin Yang, Katja K H Aben, Muriel A Adank, Simona Agata, Irene L Andrulis, Hoda Anton-Culver, Nata...> ;European Journal of Human Genetics. 2022 May 1
- Join now to see all
Journal Articles
- Variants in Genes Encoding Small GTPases and Association with Epithelial Ovarian Cancer SusceptibilityJulie M Cunningham, Robert P Edwards, Elizabeth M Poole, Tanja Pejovic, Karen Lu, Kunle Odunsi, Beth Y Karlan, Christine S Walsh, Douglas A Levine, Andrew Berchuck, Da..., PLoS One
- Functional Mechanisms Underlying Pleiotropic Risk Alleles at the 19p13.1 Breast–Ovarian Cancer Susceptibility LocusSusan M Domchek, Beth Y Karlan, Katherine L Nathanson, Kenneth Offit, Banu K Arun, Andrew Berchuck, Patricia A Ganz, Douglas A Levine, Nature
Press Mentions
- Ovarian Cancer Awareness Month; Use #IWishIKnew to Educate Women EverywhereAugust 26th, 2019
- Doctors Were Wrong When They Told Her Immunotherapy Wouldn't Cure Her CancerFebruary 20th, 2018
- Many Pelvic Tumors May Have Common OriginOctober 17th, 2017
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: